Scholarlink

<p>Hendra (HeV) and Nipah (NiV) are closely related, highly pathogenic paramyxoviruses which cause severe, often fatal disease in humans and animals. There are no approved vaccines to protect humans from HeV or NiV infection, although an ideal vaccine countermeasure should provide a protective immune response against both viruses due to the geographic overlap of the natural bat reservoir and recurrent zoonotic spillover events. Here, we developed a single-cycle, recombinant vesicular stomatitis virus vaccine displaying the HeV (G) glycoprotein (G*rVSV∆G-HeV-G) and performed vaccination, challenge, and passive transfer studies in Syrian golden hamsters. Intramuscular vaccination with a single 1.0E7 PFU dose of G*rVSV∆G-HeV-G uniformly protected from lethal HeV and NiV infection, with neutralizing antibodies elicited by the G*rVSV∆G-HeV-G vaccine identified as a correlate of protection in subsequent passive transfer experiments. Our data indicate that the experimental G*rVSV∆G-HeV-G vaccine is effective in protecting against lethal henipavirus disease in a sensitive animal model.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A single-cycle recombinant VSV vaccine displaying the Hendra virus glycoprotein uniformly protects against Hendra and Nipah virus challenge

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月3日

查看全文
  • Declan D. Pigeaud,
  • Viktoriya Borisevich,
  • Krystle N. Agans,
  • Mack B. Harrison,
  • Rachel O’Toole,
  • Jasmine Martinez,
  • Natalie S. Dobias,
  • Courtney Woolsey,
  • Karla A. Fenton,
  • Thomas W. Geisbert,
  • Robert W. Cross

摘要

Hendra (HeV) and Nipah (NiV) are closely related, highly pathogenic paramyxoviruses which cause severe, often fatal disease in humans and animals. There are no approved vaccines to protect humans from HeV or NiV infection, although an ideal vaccine countermeasure should provide a protective immune response against both viruses due to the geographic overlap of the natural bat reservoir and recurrent zoonotic spillover events. Here, we developed a single-cycle, recombinant vesicular stomatitis virus vaccine displaying the HeV (G) glycoprotein (G*rVSV∆G-HeV-G) and performed vaccination, challenge, and passive transfer studies in Syrian golden hamsters. Intramuscular vaccination with a single 1.0E7 PFU dose of G*rVSV∆G-HeV-G uniformly protected from lethal HeV and NiV infection, with neutralizing antibodies elicited by the G*rVSV∆G-HeV-G vaccine identified as a correlate of protection in subsequent passive transfer experiments. Our data indicate that the experimental G*rVSV∆G-HeV-G vaccine is effective in protecting against lethal henipavirus disease in a sensitive animal model.